If you’ve searched BPC-157 lately, you’ve probably seen headlines saying peptides are “becoming legal” or “getting approved.” Some of that is true. Most of it skips a step.
Here’s the short version. An FDA advisory committee voted to recommend six peptides for legal compounding. That is not the same as FDA actually adding them to the list. The two get mixed together a lot online, so let’s separate them.
The FDA keeps a list of substances compounding pharmacies are not allowed to prepare. That’s called Category 2. In 2023, FDA put a group of popular peptides on it, including BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon. That put them off limits for compounding pharmacies.
In April 2026, FDA removed those six from Category 2. That sounds like the green light. It isn’t. Removing a peptide from the “do not compound” list just takes away the explicit ban. It does not put the peptide on the list of substances a pharmacy is authorized to compound. Right now these six sit in between. Not banned outright, but not approved either.
On July 23 and 24, 2026, FDA’s Pharmacy Compounding Advisory Committee met to decide whether to recommend adding these peptides to the approved list, known as the 503A Bulk Drug Substances List. This is the part that made headlines.
The committee voted to recommend all six. The votes were close, mostly 7 or 8 in favor against 4 to 6 against. A seventh peptide up for the same vote, emideltide, did not get enough support and failed.
Here’s the part a lot of coverage left out. FDA’s own staff recommended against adding these peptides, citing safety and efficacy concerns. The committee voted to recommend them anyway. That disagreement between FDA staff and the advisory committee matters. It means this isn’t a settled scientific consensus. It’s a close, contested vote that went against the agency’s own recommendation.
An advisory committee vote is just that. Advice. FDA still has to run a formal rulemaking process to actually add these peptides to the approved list. That process involves public notice, a comment period, and a final decision. Legal trackers following this closely are estimating it could stretch into 2027 or later. As of this writing, FDA hasn’t started that formal process, and there’s no interim policy letting compounding go ahead in the meantime.
You may have also seen Robert F. Kennedy Jr., who runs Health and Human Services, talk publicly about restoring access to these peptides and calling the 2023 restrictions unlawful. That’s worth knowing about, but it’s a policy position, not an action. It hasn’t changed anything about what’s currently legal.
As of today, BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon are not authorized for pharmacy compounding. An advisory panel has recommended they be added to the approved list. FDA has not yet done that, and the process to get there is still ahead of us, likely well into next year at the earliest.
If someone tells you these peptides are now legal to compound, they’re a step ahead of where things actually stand. Recommended is not the same as approved. We’ll keep this page updated as the rulemaking moves, because right now, updating is about all there is to report.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.